Bevacizumab prescribing practices for epithelial ovarian cancer in Australia

Nikki Burdett, Ganessan Kichenadasse

    Research output: Contribution to journalComment/debate

    Abstract

    Ovarian cancer represents a source of significant morbidity and mortality in developed countries. In 2018, it was the eighth most common cancer in females worldwide.1 While the age‐specific incidence has decreased, the absolute number of diagnoses has increased. In 2012, in Australia, there were 1384 new cases of ovarian cancer; in 2014 it was 1395...
    Original languageEnglish
    Pages (from-to)1334-1335
    Number of pages2
    JournalInternal Medicine Journal
    Volume49
    Issue number10
    DOIs
    Publication statusPublished - 1 Oct 2019

    Keywords

    • Bevacizumab
    • Ovarian cancer
    • patient outcomes
    • prescribing practices

    Fingerprint Dive into the research topics of 'Bevacizumab prescribing practices for epithelial ovarian cancer in Australia'. Together they form a unique fingerprint.

    Cite this